8-K: STAAR Surgical Reports Strong Q1 2026 Preliminary Sales

STAAR Surgical announced preliminary Q1 2026 net sales exceeding $90 million, a significant increase from the prior year, driven by strong performance in China and the Americas.

Summary

• STAAR Surgical Company has released preliminary net sales figures for the first quarter ended April 3, 2026.
• Net sales are expected to be over $90 million, a substantial increase from $42.6 million in the first quarter of 2025.
• The company attributes this growth primarily to strong sales in China and continued double-digit growth in the Americas.
• Improved cost structure is anticipated to lead to a meaningful improvement in adjusted EBITDA for the quarter.
• The company is providing these preliminary results in advance of its full earnings announcement to engage with the investment and ophthalmology communities at the ASCRS Annual Meeting.
• Full first quarter financial results are expected to be reported in early May 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal due to the significant year-over-year revenue growth and anticipated EBITDA improvement, despite acknowledging some regional challenges.

Positives

• Preliminary net sales for Q1 2026 are expected to exceed $90 million, more than double the $42.6 million reported in Q1 2025.
• Significant growth in China, the company's largest market, is a key driver of the sales increase.
• Continued double-digit growth in the Americas is also contributing to the positive sales performance.
• The company anticipates a meaningful improvement in adjusted EBITDA due to higher net sales and an improved cost structure.
• Distributor inventory in China appears to be within the company's targeted range as of the end of Q1 2026.

Negatives

• Net sales in the Middle East and some parts of EMEA and APAC regions were negatively affected by significant geopolitical and macroeconomic challenges.
• The company cautions that sales growth could continue to be adversely affected if these challenging conditions persist, and macroeconomic challenges could spread to other regions.

Risks

• Current global business conditions are volatile and some portions of the business remain unpredictable.
• Geopolitical and macroeconomic challenges in the Middle East and parts of EMEA and APAC regions have negatively impacted sales.
• There is a risk that sales growth could continue to be adversely affected if these conditions persist.
• Macroeconomic challenges could spread to other regions.
• The company relies on independent distributors in international markets.
• Potential for disruptions in the supply chain.
• Fluctuations in foreign currency exchange rates.
• International trade disputes, including tariffs, and substantial dependence on demand from Asia.

Future Outlook

The company is not providing forward revenue or earnings guidance. They expect to report full first quarter financial results and file their 10-Q in early May 2026. The company cautions that sales growth could continue to be adversely affected by geopolitical and macroeconomic challenges if they persist.

Management Comments

• "We are very pleased with our strong first quarter net sales in our largest market, China, which accounted for the majority of the increase in net sales, along with continued double-digit growth in the Americas."
• "Our higher net sales, combined with our significantly improved cost structure, are expected to drive a meaningful improvement in adjusted EBITDA for the first quarter."
• "These results deliver on two of the three core objectives outlined in our Shareholder Letter earlier this year-Revenue Growth and Profit Expansion-and though early in the year, are indicators of the overall good health of our business."
• "Current global business conditions are volatile and some portions of our business remain unpredictable."
• "We continue to provide no forward revenue or earnings guidance and look forward to reporting our full first quarter financial results and filing our 10-Q in early May."
• "The Company is monitoring the situation and cautions that sales growth could continue to be adversely affected if these conditions persist, and that macroeconomic challenges could spread to other regions."

Industry Context

StockSavvy.ai notes that STAAR Surgical's preliminary results highlight a strong rebound in its key Chinese market and continued growth in the Americas, a positive sign in the competitive vision correction industry. However, the company's acknowledgment of geopolitical and macroeconomic headwinds in other regions underscores broader industry concerns about global economic stability impacting specialized medical device markets.

Stakeholder Impact

• Shareholders: Potential for positive impact on stock price due to strong preliminary financial results and improved profitability outlook.
• Employees: Positive morale boost from strong company performance, potentially leading to better job security and opportunities.
• Surgeons and Ophthalmology Community: Continued availability of EVO ICLs and potential for further product development driven by strong sales.
• Distributors: Improved sales environment, particularly in China, with inventory levels normalizing.

Next Steps

• Report full first quarter financial results in early May 2026.
• File the Form 10-Q for the quarter ended April 3, 2026, in early May 2026.
• Continue to monitor geopolitical and macroeconomic challenges and their potential impact on sales.
• Engage with the investment community and ophthalmology community at the ASCRS Annual Meeting.

Key Dates

Recommendation

While the preliminary results show very strong growth, the company explicitly states it is not providing forward guidance and acknowledges significant geopolitical and macroeconomic risks that could impact future performance. The strong Q1 performance is positive, but the uncertainty surrounding global conditions warrants a cautious 'hold' until full results and updated outlook are provided.

Keywords

STAAR Surgical, EVO ICL, Phakic IOLs, Vision Correction, Ophthalmology, Preliminary Sales, Net Sales, EBITDA